George A. Fisher Jr.

Publications

• Seventh edition (2010) of the AJCC/UICC staging system for gastric adenocarcinoma: is there room for improvement? Patel MI, Rhoads KF, Ma Y, Ford JM, Visser BC, Kunz PL, Fisher GA, Chang DT, Koong A, Norton JA, Poultsides GA. Ann Surg Oncol. 2013; 20 (5): 1631-8
• A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. Padda SK, Krupitskaya Y, Chhatwani L, Fisher GA, Colevas AD, San Pedro-Salcedo M, Decker R, Latz JE, Wakelee HA. Cancer Chemother Pharmacol. 2012; 69 (4): 1013-20
• A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. Cabebe EC, Fisher GA, Sikic BI. Invest New Drugs. 2012; 30 (3): 1082-7
• Capecitabine-induced chest pain relieved by diltiazem. Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Am J Cardiol. 2012; 110 (11): 1623-6
• Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK. Mod Pathol. 2012; 25 (8): 1128-39
• HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. Appl Immunohistochem Mol Morphol. 2012; 20 (1): 13-24
• Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, Kunz P, Norton JA, Visser BC, Poultsides GA, Koong AC, Chang DT. Int J Radiat Oncol Biol Phys. 2012; 82 (4): e595-601
• Long-term survivors of gastric cancer: a California population-based study. Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. J Clin Oncol. 2012; 30 (28): 3507-15
• Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis. Poultsides GA, Huang LC, Chen Y, Visser BC, Pai RK, Jeffrey RB, Park WG, Chen AM, Kunz PL, Fisher GA, Norton JA. Ann Surg Oncol. 2012; 19 (7): 2295-303
• 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. Zissen MH, Kunz P, Subbarayan M, Chin FT, Conti PS, Fisher GA, Quon A. Nucl Med Commun. 2011; 32 (5): 343-7
• Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. J Clin Oncol. 2011; 29 (7): 934-43
• Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Bazan JG, Hara W, Hsu A, Kunz PA, Ford J, Fisher GA, Welton ML, Shelton A, Kapp DS, Koong AC, Goodman KA, Chang DT. Cancer. 2011; 117 (15): 3342-51
• Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Norton JA, Harris EJ, Chen Y, Visser BC, Poultsides GA, Kunz PC, Fisher GA, Jensen RT. Arch Surg. 2011; 146 (6): 724-32
• Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies. Galatin PS, Advani RH, Fisher GA, Francisco B, Julian T, Losa R, Sierra MI, Sikic BI. Invest New Drugs. 2011; 29 (5): 971-7
• Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Kunz PL, Fisher GA. Clin Exp Gastroenterol. 2010: 3 79-86
• Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Minn AY, Hsu A, La T, Kunz P, Fisher GA, Ford JM, Norton JA, Visser B, Goodman KA, Koong AC, Chang DT. Cancer. 2010; 116 (16): 3943-52
• Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Chang DT, Chapman CH, Norton JA, Visser B, Fisher GA, Kunz P, Ford JM, Koong AC, Pai RK. Cancer. 2010; 116 (22): 5179-87
• Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. La TH, Minn AY, Su Z, Fisher GA, Ford JM, Kunz P, Goodman KA, Koong AC, Chang DT. Dis Esophagus. 2010; 23 (4): 300-8
• Pathological response after chemoradiation for T3 rectal cancer. Chennupati SK, Kamaya A, Fisher GA, Ford JM, Kunz P, Itakura H, Welton ML, Shelton A, Van Dam J, Koong AC, Chang DT. Colorectal Dis. 2010; 12 (7 Online): e24-30
• Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, Ullrich SJ, Fisher GA, Tolcher AW. Ann Oncol. 2010; 21 (2): 376-81
• Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. Chang ST, Zahn JM, Horecka J, Kunz PL, Ford JM, Fisher GA, Le QT, Chang DT, Ji H, Koong AC. J Transl Med. 2009: 7 105
• Impaired interferon signaling is a common immune defect in human cancer. Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL, Swetter SM, Carlson RW, Fisher GA, Koong A, Holmes S, Lee PP. Proc Natl Acad Sci U S A. 2009; 106 (22): 9010-5
• Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC. Cancer. 2009; 115 (3): 665-72
• A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Fisher GA, Kuo T, Ramsey M, Schwartz E, Rouse RV, Cho CD, Halsey J, Sikic BI. Clin Cancer Res. 2008; 14 (21): 7074-9
• Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Telli ML, Witteles RM, Fisher GA, Srinivas S. Ann Oncol. 2008; 19 (9): 1613-8
• Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J, Greco R, Yang GP, Koong AC. Int J Radiat Oncol Biol Phys. 2008; 72 (3): 678-86
• Phase II study of imatinib in unresectable hepatocellular carcinoma. Lin AY, Fisher GA, So S, Tang C, Levitt L. Am J Clin Oncol. 2008; 31 (1): 84-8
• Tissue effects after stereotactic body radiotherapy using cyberknife for patients with abdominal malignancies. Cupp JS, Koong AC, Fisher GA, Norton JA, Goodman KA. Clin Oncol (R Coll Radiol). 2008; 20 (1): 69-75
• Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer. Cabebe E, Fisher GA. Expert Opin Investig Drugs. 2007; 16 (4): 467-76
• NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J. J Natl Compr Canc Netw. 2007: 5 Suppl 2 S1-29; quiz S30
• Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. Street HH, Goris ML, Fisher GA, Wessels BW, Cho C, Hernandez C, Zhu HJ, Zhang Y, Nangiana JS, Shan JS, Roberts K, Knox SJ. Cancer Biother Radiopharm. 2006; 21 (3): 243-56
• Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. Cho CD, Fisher GA, Halsey J, Sikic BI. Invest New Drugs. 2006; 24 (2): 117-23
• A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Advani R, Lum BL, Fisher GA, Halsey J, Geary RS, Holmlund JT, Kwoh TJ, Dorr FA, Sikic BI. Invest New Drugs. 2005; 23 (5): 467-77
• A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer. Wakelee H, Fisher GA. Invest New Drugs. 2005; 23 (3): 241-2
• A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. Advani R, Lum BL, Fisher GA, Halsey J, Chin DL, Jacobs CD, Sikic BI. Ann Oncol. 2005; 16 (12): 1968-73
• Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer. Kuo T, Fisher GA. Clin Colorectal Cancer. 2005: 5 Suppl 2 S62-70
• Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI. J Clin Oncol. 2005; 23 (24): 5613-9
• Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock TI, Levitt L. Cancer. 2005; 103 (1): 119-25
• Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Koong AC, Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J, Yang GP. Int J Radiat Oncol Biol Phys. 2005; 63 (2): 320-3
• A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, Holmlund JT, Dorr A, Sikic BI. Cancer. 2004; 100 (2): 321-6
• Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Koong AC, Le QT, Ho A, Fong B, Fisher G, Cho C, Ford J, Poen J, Gibbs IC, Mehta VK, Kee S, Trueblood W, Yang G, Bastidas JA. Int J Radiat Oncol Biol Phys. 2004; 58 (4): 1017-21
• Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Advani R, Fisher GA, Lum BL, Jambalos C, Cho CD, Cohen M, Gollerkeri A, Sikic BI. Clin Cancer Res. 2003; 9 (14): 5187-94
• Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Mehta VK, Cho C, Ford JM, Jambalos C, Poen J, Koong A, Lin A, Bastidas JA, Young H, Dunphy EP, Fisher G. Int J Radiat Oncol Biol Phys. 2003; 55 (1): 132-7
• Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. Mehta VK, Fisher G, Ford JA, Poen JC, Vierra MA, Oberhelman H, Niederhuber J, Bastidas JA. J Gastrointest Surg. 2001 Jan-Feb; 5 (1): 27-35
• Center experience in liver transplantation for hepatocellular carcinoma associated with cirrhosis. Lai KM, Millan M, Razavi M, Keeffe EB, Prapong W, Fisher GA, Esquivel CO, So SK. Transplant Proc. 2001 Feb-Mar; 33 (1-2): 1490-1
• A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, Sikic BI. Clin Cancer Res. 2001; 7 (5): 1221-9
• Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of Vater: preliminary report. Mehta VK, Fisher GA, Ford JM, Poen JC, Vierra MA, Oberhelman HA, Bastidas AJ. Arch Surg. 2001; 136 (1): 65-9
• Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG. Proc Natl Acad Sci U S A. 2001; 98 (15): 8809-14
• Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Mehta VK, Poen JC, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, Fisher GA. Am J Clin Oncol. 2001; 24 (2): 155-9
• Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. Mehta VK, Poen J, Ford J, Edelstein PS, Vierra M, Bastidas AJ, Young H, Fisher G. Dis Colon Rectum. 2001; 44 (1): 52-8
• Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Mehta VK, Fisher GA, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, Poen JC. Int J Radiat Oncol Biol Phys. 2000; 48 (5): 1483-7
• Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. Lum BL, Kaubisch S, Fisher GA, Brown BW, Sikic BI. Cancer Chemother Pharmacol. 2000; 45 (4): 305-11
• Pancreatic tumors show high levels of hypoxia. Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, Bastidas AJ, Vierra M. Int J Radiat Oncol Biol Phys. 2000; 48 (4): 919-22
• Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Sikic BI. Clin Cancer Res. 1999; 5 (11): 3357-63
• Chemo-radiotherapy for localized pancreatic cancer: increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil. Poen JC, Collins HL, Niederhuber JE, Oberhelman HA, Vierra MA, Bastidas AJ, Young HS, Slosberg EA, Jeffrey BR, Longacre TA, Fisher GA, Goffinet DR. Int J Radiat Oncol Biol Phys. 1998; 40 (1): 93-9
• Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Cancer Chemother Pharmacol. 1997: 40 Suppl S13-9
• Pharmacological considerations in the modulation of multidrug resistance. Fisher GA, Lum BL, Hausdorff J, Sikic BI. Eur J Cancer. 1996; 32A (6): 1082-8
• Clinical studies with modulators of multidrug resistance. Fisher GA, Sikic BI. Hematol Oncol Clin North Am. 1995; 9 (2): 363-82
• Drug resistance in clinical oncology and hematology. Introduction. Fisher GA, Sikic BI. Hematol Oncol Clin North Am. 1995; 9 (2): xi-xii
• The reversal of multidrug resistance. Fisher GA, Lum BL, Sikic BI. Cancer Treat Res. 1995: 78 45-70
• Mammalian cell survival studies characterizing multiport negative pi-meson irradiation with the Stanford Medical Pion Generator (SMPG). Li GC, Fessenden P, Hahn GM, Fisher G, Luxton G, Bagshaw MA. Int J Hyperthermia. 1994 May-Jun; 10 (3): 361-70
• Clinical reversal of multidrug resistance. Sikic BI, Fisher GA, Lum BL, Brophy NA, Yahanda AM, Adler KM, Halsey J. Cancer Treat Res. 1994: 73 149-65
• Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI. J Clin Oncol. 1994; 12 (4): 835-42
• Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J, Sikic BI. Cancer. 1993; 72 (11 Suppl): 3502-14
• Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. Yahanda AM, Alder KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI. J Clin Oncol. 1992; 10 (10): 1624-34
• DNA damage does not appear to be a trigger for thermotolerance in mammalian cells. Anderson RL, Shiu E, Fisher GA, Hahn GM. Int J Radiat Biol. 1988; 54 (2): 285-98
• Correlation of mammalian cell killing by heat shock to intramembranous particle aggregation and lateral phase separation using fluorescence-activated cell sorting. Rice GC, Fisher KA, Fisher GA, Hahn GM. Radiat Res. 1987; 112 (2): 351-64